All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
Nelson, David R., Cooper, James N., Lalezari, Jacob P., Lawitz, Eric, Pockros, Paul J., Gitlin, Norman, Freilich, Bradley F., Younes, Ziad H., Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J., Ortiz‐Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M., Varunok, Peter, Kowdley, Kris V., Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A.
Published in Hepatology (Baltimore, Md.) (01.04.2015)
Published in Hepatology (Baltimore, Md.) (01.04.2015)
Get full text
Journal Article
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks
Rodríguez-Torres, Maribel, Ríos-Bedoya, Carlos F, Ortiz-Lasanta, Grisell, Purcell-Arevalo, Dagmary, Marxuach-Cuétara, Acisclo, Jiménez-Rivera, Josselyn
Published in Journal of medical virology (01.09.2008)
Published in Journal of medical virology (01.09.2008)
Get full text
Journal Article
Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis
Rodríguez-Torres, Maribel, Ríos-Bedoya, Carlos F, Ortiz-Lasanta, Grisell, Marxuach-Cuétara, Acisclo M, Jiménez-Rivera, Josselyn
Published in Annals of hepatology (01.01.2008)
Published in Annals of hepatology (01.01.2008)
Get full text
Journal Article
BIO89-100 Demonstrated Robust Reductions in Liver Fat, Improved Metabolic Parameters, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH
Frias, Juan Pablo, Ortiz-Lasanta, Grisell, Hartsfield, Cynthia L., Tseng, Leo, Charlton, R. William, Mansbach, Hank, Margalit, Maya, Loomba, Rohit
Published in Metabolism, clinical and experimental (01.03.2022)
Published in Metabolism, clinical and experimental (01.03.2022)
Get full text
Journal Article
Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
Poordad, Fred, Sievert, William, Mollison, Lindsay, Bennett, Michael, Tse, Edmund, Bräu, Norbert, Levin, James, Sepe, Thomas, Lee, Samuel S, Angus, Peter, Conway, Brian, Pol, Stanislas, Boyer, Nathalie, Bronowicki, Jean-Pierre, Jacobson, Ira, Muir, Andrew J, Reddy, K. Rajender, Tam, Edward, Ortiz-Lasanta, Grisell, de Lédinghen, Victor, Sulkowski, Mark, Boparai, Navdeep, McPhee, Fiona, Hughes, Eric, Swenson, E. Scott, Yin, Philip D
Published in JAMA : the journal of the American Medical Association (05.05.2015)
Published in JAMA : the journal of the American Medical Association (05.05.2015)
Get full text
Journal Article
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study
Loomba, Rohit, Lawitz, Eric J, Frias, Juan Pablo, Ortiz-Lasanta, Grisell, Johansson, Lars, Franey, Bridgette Boggess, Morrow, Linda, Rosenstock, Moti, Hartsfield, Cynthia L, Chen, Chao-Yin, Tseng, Leo, Charlton, R Will, Mansbach, Hank, Margalit, Maya
Published in The lancet. Gastroenterology & hepatology (01.02.2023)
Published in The lancet. Gastroenterology & hepatology (01.02.2023)
Get more information
Journal Article
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
Orkin, Chloe, Molina, Jean-Michel, Cahn, Pedro, Lombaard, Johannes, Supparatpinyo, Khuanchai, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, Lahoulou, Rima
Published in The lancet HIV (01.02.2024)
Published in The lancet HIV (01.02.2024)
Get more information
Journal Article
BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH
Frias, Juan Pablo, Lawitz, Eric J, Ortiz-LaSanta, Grisell, Franey, Bridgette, Morrow, Linda, Chen, Chao-Yin, Tseng, Leo, Charlton, R William, Mansbach, Hank, Margalit, Maya, Loomba, Rohit
Published in Journal of the Endocrine Society (03.05.2021)
Published in Journal of the Endocrine Society (03.05.2021)
Get full text
Journal Article